{"id":"NCT00377819","sponsor":"Amgen","briefTitle":"Study of Transitioning From Alendronate to Denosumab","officialTitle":"A Randomized Study to Evaluate Safety and Efficacy of Transitioning Therapy From Alendronate to Denosumab (AMG 162) in Postmenopausal Women With Low Bone Mineral Density","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2006-09","primaryCompletion":"2008-03","completion":"2008-07","firstPosted":"2006-09-18","resultsPosted":"2010-08-03","lastUpdate":"2011-07-11"},"enrollment":504,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"QUADRUPLE","primaryPurpose":"TREATMENT"},"conditions":["Postmenopausal Osteoporosis"],"interventions":[{"type":"DRUG","name":"alendronate","otherNames":[]},{"type":"DRUG","name":"Denosumab (AMG 162)","otherNames":[]}],"arms":[{"label":"denosumab","type":"EXPERIMENTAL"},{"label":"alendronate","type":"ACTIVE_COMPARATOR"}],"summary":"The study will evaluate the efficacy and safety of transitioning postmenopausal women on current alendronate therapy to denosumab. Endpoints studied will include bone mineral density, bone turnover markers and bone histology in a subset of subjects.","primaryOutcome":{"measure":"Percent Change From Baseline in Total Hip Bone Mineral Density","timeFrame":"Baseline, 12 months","effectByArm":[{"arm":"Alendronate 70 mg QW","deltaMin":1.05,"sd":null},{"arm":"Denosumab 60 mg Q6M","deltaMin":1.9,"sd":null}],"pValues":[{"comp":"OG000 vs OG001","p":"<0.0001"}]},"eligibility":{"minAge":"55 Years","sex":"FEMALE","healthyVolunteers":false,"inclusionCount":3,"exclusionCount":6},"locations":{"siteCount":0,"countries":[]},"refs":{"pmids":["19594293","31776637","22152181","20533525"],"seeAlso":["http://download.veritasmedicine.com/REGFILES/amgen/Amgen_results_disclaimer.pdf","http://www.amgentrials.com"]},"adverseEventsSummary":{"seriousAny":{"events":16,"n":249},"commonTop":["Nasopharyngitis","Back pain","Arthralgia","Pain in extremity","Bronchitis"]}}